Insights with Innovators
Future of Small and Mid-Tier Pharma Marketing
Roundtable Discussion
![social media - COVID-19](https://digitalhealthcoalition.org/wp-content/uploads/2020/03/social-media-feature-1024.png)
Summary
In this interview, Mark Bard (Co-Founder of the DHC Group) discusses the future of small and mid-tier pharma marketing with Chris Tuleya (EVP & Managing Director) and Jay de la Cruz (SVP, Media) of Underscore Marketing.
Interview
![](https://digitalhealthcoalition.org/wp-content/uploads/2019/03/MarkBard-150x150.jpg)
Mark Bard
Co-Founder
DHC Group
![chris-tuleya](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/chris-tuleya-headshot-150x150.png)
Chris Tuleya
EVP & Managing Director
Underscore Marketing
![](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/jay-de-la-cruz-headshot-150x150.png)
Jay de la Cruz
SVP, Media
Underscore Marketing
![](https://digitalhealthcoalition.org/wp-content/uploads/2019/03/MarkBard-150x150.jpg)
Mark Bard
Co-Founder
DHC Group
![](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/jay-de-la-cruz-headshot-150x150.png)
Jay de la Cruz
SVP, Media
Underscore Marketing
“Telehealth is here to stay. The pandemic saw a surge in telehealth engagements. While it has leveled out, telehealth usage is still high compared to pre-pandemic. Telehealth has also been an important channel to incorporate patient support program enrollments and sustain support to access therapy.
Proactively connecting with patients instead of reacting will continue to be a long-term strategy. Small and mid-tier pharma companies will invest in the patient community, building out influencer networks and leveraging social as a primary channel.
Continuously improving how they connect with patients. The pandemic increased the need to hyper focus on financial assistance and limit barriers to access. A means to achieve this is through increased investment in developing CRM to maintain contact and listen to their patients.
Small and mid-tier pharma companies will continue to drive innovation in drug therapy development.”
![](https://digitalhealthcoalition.org/wp-content/uploads/2019/03/MarkBard-150x150.jpg)
Mark Bard
Co-Founder
DHC Group
![chris-tuleya](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/chris-tuleya-headshot-150x150.png)
Chris Tuleya
EVP & Managing Director
Underscore Marketing
![](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/jay-de-la-cruz-headshot-150x150.png)
Jay de la Cruz
SVP, Media
Underscore Marketing
![](https://digitalhealthcoalition.org/wp-content/uploads/2019/03/MarkBard-150x150.jpg)
Mark Bard
Co-Founder
DHC Group
![chris-tuleya](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/chris-tuleya-headshot-150x150.png)
Chris Tuleya
EVP & Managing Director
Underscore Marketing
![](https://digitalhealthcoalition.org/wp-content/uploads/2019/03/MarkBard-150x150.jpg)
Mark Bard
Co-Founder
DHC Group
![chris-tuleya](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/chris-tuleya-headshot-150x150.png)
Chris Tuleya
EVP & Managing Director
Underscore Marketing
![](https://digitalhealthcoalition.org/wp-content/uploads/2021/12/jay-de-la-cruz-headshot-150x150.png)